NIH Knowledge Portal for Diabetes Researchers and General Public

هذه الأداة المعرفية Knowledge tool مثلها مثل العديد من الأدوات المعرفية الأخرى تعتبر حديثة النشوء وفي تطور وديناميكية مستمرة. والدليل على ذلك إختلاف عنونتها في الصفحات المختلفة وإختلاف وصفها.

لكن يبقى شئ مهم هو إهتمام هيئة خدمية هامة مثل الNIH وشركائها بإنشاء هذه الأداة المعرفية لإدراكها أهمية مساهمتها في علاج مرض رهيب إنتشر كالوباء وهو مرض السكري.

أمثلة لإختلاف العنونة والوصف

مرجع ذلك أن الأداة المعرفية في مرحلة تطور وديناميكية مستمرة.

• NIH Knowledge Portal for Diabetes Researchers and General Public
  • NIH Knowledge Portal for Diabetes Researchers and General Public بوابة معرفية للباحثين وللعامة
  • Online library on genetic and clinical data concerning diabetes type 2 is available مكتبة على الإنترنت
  • newly launched online library, known as knowledge portal, that permits open-access searching of clinical information and human genetic data on type 2 diabetes. مكتبة على الإنترنت وبوابة معرفية للبحث المفتوح المصدر.
  • The portal incorporates data from many global networks, gathered through decades of investigation. معلومات مجمعة من شبكات
  • The portal results from the Accelerating Medicines Partnership (AMP) for type 2 diabetes seeks to advance the research and treatment of the disorder. الهدف هو تقدم البحوث والعلاج
    • The National Institutes of Health (NIH), 10 biopharmaceutical companies, and multiple non-profit organizations launched an unprecedented new public-private partnership in February 2014. Managed through the Foundation for the NIH (FNIH), the Accelerating Medicines Partnership (AMP) brings high-level government, industry, and non-profit foundation partners together to identify and validate the most promising biological targets for therapeutics . The partners have designed a bold milestone-driven research plan to tackle this challenge for type 2 diabetes, as well as for Alzheimer’s disease and the autoimmune disorders rheumatoid arthritis and systemic lupus erythematosus (lupus). What makes this public-private partnership unique is that AMP data will be considered precompetitive and made publicly accessible to the broad biomedical community for further research. This fact sheet addresses the AMP research plan for type 2 diabetes. يلاحظ أنها تستهدف أمراض أخرى فيما بعد مثل الألزهيمر وأمراض مناعية أخرى. كما يلاحظ أنها توصف انها مشروع غير مسبوق. وأنها شراكة بين جاهات متعددة (نتحفظ على وجود شركات الأدوية لأنها في تلك البلاد عليها رقابة صارمة ولا تتلاعب بالحقائق بشكل عام على عكس بلادنا بشكل عام). وأن المشروع متاح للعامة ووللمجتمع البحثي ومفتوح المصدر.

• • portal – and this partnership – will lead to better disease targets and a shorter, less expensive drug development process, enabling companies to get safe and effective medications to patients who need them faster إذا الهدف هو الإسراع بتحسين الخدمة المقدمة للوصول للهدف المطلوب وتوفير وقت وجهد وصحة.

• • The portal can be accessed publicly and can be utilized as a device to study health and genetics. Nonetheless, only permitted investigators will have access to detailed information, whereas the general community can access aggregate data. The research engine inventors are enthusiastic to magnify the network to incorporate more international and research networks. The international source samples of clinical and genetic information will be kept in their home networks to guarantee that the use of each clinical sample fulfills each country’s health data confidentiality policies.

• من صفحة البوابة الرسمية: About the portal

This portal provides access to comprehensive results from 28 large human genetic association studies of type 2 diabetes and related traits that used sequencing or genotyping arrays. These data can shed light on biological functions of genes and point to possible drug targets.

• • http://www.type2diabetesgenetics.org/ إسم الموقع يوحي انه يستهدف الجينات فقط على الرغم من أنه يستهدف العلاج والبحوث بشكل عام.

الإشارة للبوابة

Citing portal data Users who wish to cite data in this Portal in a scientific publication should do so in the following format:

AMP-T2D Program; T2D-GENES Consortium, SIGMA T2D Consortium. Year/Month/Date of access; URL of page you are citing.

For instance, a user who viewed the Portal's page on the gene SLC30A8 on February 1, 2015, and wanted to cite it would use this citation:

AMP-T2D Program; T2D-GENES Consortium, SIGMA T2D Consortium. type2diabetesgenetics.org. 2015 Feb 1; http://www.type2diabetesgenetics.org/gene/geneInfo/SLC30A8.

The Portal does not yet have a PubMed identifier.

Please use the following citation when referring to data from this portal: AMP T2D-GENES Program, SIGMA; Year Month Date of Access; URL of page you are citing.

إستخدام البيانات

Data use

POLICIES AND PLAN FOR DATA IN THE T2D KNOWLEDGE PORTAL

The Broad Institute will serve as the Data Coordinating Center (DCC) for AMP-T2D. On behalf of AMP-T2D, the DCC will aggregate data, support analyses, and continue to update capabilities to disseminate results relevant to the genetics of T2D (T2D) and related traits, while coordinating collaboration within the AMP-T2D Project.

وتوجد طريقة محددة لإستخدام المعلومات.

Data use and availability

All users are welcome to use results from analyses of the data in the Portal to further their research without seeking explicit permission from the Portal team or funders. Users are also welcome to cite data in scientific publications, provided that they cite the Portal as the source. If users are citing a single dataset represented in the Portal, they should cite both the Portal and the relevant paper for that dataset (if one has been published).

نقل المعارف من مكانها الأصلي

information will be kept in their home networks to guarantee that the use of each clinical sample fulfills each country’s health data confidentiality policies.

ترخيص الموقع

Re-using written content on the portal Except where otherwise noted, text on this site is licensed under a Creative Commons Attribution Non-Commercial Share Alike 4.0 International License.